Učitavanje...
Bromocriptine in type 2 diabetes mellitus
Bromocriptine mesylate quick-release was approved by the Food and Drug Administration (FDA) in May 2009, for the treatment of type 2 diabetes. Bromocriptine is thought to act on the circadian neuronal activities in the hypothalamus, to reset an abnormally elevated hypothalamic drive for increased pl...
Spremljeno u:
| Glavni autori: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Medknow Publications
2011
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3152192/ https://ncbi.nlm.nih.gov/pubmed/21847449 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2230-8210.83058 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|